학술논문
Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus
Document Type
Academic Journal
Author
Source
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. May 31, 2020, p1855, 6 p.
Subject
Language
English
ISSN
1178-7007
Abstract
Introduction Diabetes mellitus is one of the most common metabolic disorders characterized by hyperglycemia. (1) It occurs due to absolute or partial lack of insulin and/or insulin resistance. (2) Diabetes [...]
Diabetes mellitus (DM) is a worldwide health threat affecting millions of people, which is associated with different micro- and macro-vascular complications. Type 2 diabetes mellitus (T2DM) is one of the different types of DM caused by insulin resistance and/or reduced secretion of insulin from the pancreas. A validated novel biomarker is required to enhance the accuracy of disease prediction, provide novel insights into pathophysiology and contribute to future prevention of T2DM. Various newer diagnostic methods have been developed by targeting endogenous proteins among which Adipsin is one of the promising target. Therefore, this review discusses Adipsin as a potential biomarker and its implication in T2DM. Adipsin is one of the adipokines secreted by adipose tissues which is involved in maintaining adipose tissue homeostasis and increasing insulin secretion in response to glucose. According to different experimental and clinical studies, plasma Adipsin concentrations are low in animals and patients with DM which support its use as a biomarker in combination to the other diagnostic modalities for DM. Additionally, the existence of Adipsin could be important in improving hyperglycemia by preserving ([beta]-cell mass through improving ([beta]-cell survival and maintaining their transcriptional identity. Keywords: adipsin, type 2 diabetes mellitus, biomarker
Diabetes mellitus (DM) is a worldwide health threat affecting millions of people, which is associated with different micro- and macro-vascular complications. Type 2 diabetes mellitus (T2DM) is one of the different types of DM caused by insulin resistance and/or reduced secretion of insulin from the pancreas. A validated novel biomarker is required to enhance the accuracy of disease prediction, provide novel insights into pathophysiology and contribute to future prevention of T2DM. Various newer diagnostic methods have been developed by targeting endogenous proteins among which Adipsin is one of the promising target. Therefore, this review discusses Adipsin as a potential biomarker and its implication in T2DM. Adipsin is one of the adipokines secreted by adipose tissues which is involved in maintaining adipose tissue homeostasis and increasing insulin secretion in response to glucose. According to different experimental and clinical studies, plasma Adipsin concentrations are low in animals and patients with DM which support its use as a biomarker in combination to the other diagnostic modalities for DM. Additionally, the existence of Adipsin could be important in improving hyperglycemia by preserving ([beta]-cell mass through improving ([beta]-cell survival and maintaining their transcriptional identity. Keywords: adipsin, type 2 diabetes mellitus, biomarker